239 related articles for article (PubMed ID: 24825019)
1. Adverse events of targeted therapies.
Klastersky JA
Curr Opin Oncol; 2014 Jul; 26(4):395-402. PubMed ID: 24825019
[TBL] [Abstract][Full Text] [Related]
2. Review: side effects of approved molecular targeted therapies in solid cancers.
Widakowich C; de Castro G; de Azambuja E; Dinh P; Awada A
Oncologist; 2007 Dec; 12(12):1443-55. PubMed ID: 18165622
[TBL] [Abstract][Full Text] [Related]
3. Molecular targeted therapies for solid tumors: management of side effects.
Grünwald V; Soltau J; Ivanyi P; Rentschler J; Reuter C; Drevs J
Onkologie; 2009 Mar; 32(3):129-38. PubMed ID: 19295254
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular toxicities of biological therapies.
Ryberg M
Semin Oncol; 2013 Apr; 40(2):168-77. PubMed ID: 23540742
[TBL] [Abstract][Full Text] [Related]
5. Dermatological side effects of current and upcoming targeted therapies in oncology.
Bonny M; Buyse V; Brochez L
Acta Clin Belg; 2011; 66(2):97-103. PubMed ID: 21630605
[TBL] [Abstract][Full Text] [Related]
6. [Management of adverse effects of targeted therapy toxicities in oncology].
Coquan E; Henri P; de Raucourt S; Lireux B; Lamy E; Delcambre C; Sevin E; Dutriaux C; Bouhier-Leporrier K; Gervais R; Joly F
Rev Prat; 2012 Jan; 62(1):17-25. PubMed ID: 22335060
[TBL] [Abstract][Full Text] [Related]
7. Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy.
Maurea N; Coppola C; Ragone G; Frasci G; Bonelli A; Romano C; Iaffaioli RV
J Cardiovasc Med (Hagerstown); 2010 Dec; 11(12):861-8. PubMed ID: 20072001
[TBL] [Abstract][Full Text] [Related]
8. Metabolic disorders associated with the use of targeted cancer therapies.
Kotecki N; Penel N; Awada A
Curr Opin Oncol; 2015 May; 27(3):258-66. PubMed ID: 25730544
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies: a new generation of cancer treatments.
Gerber DE
Am Fam Physician; 2008 Feb; 77(3):311-9. PubMed ID: 18297955
[TBL] [Abstract][Full Text] [Related]
10. Side effects of targeted therapies: rash.
Eaby-Sandy B; Lynch K
Semin Oncol Nurs; 2014 Aug; 30(3):147-54. PubMed ID: 25085026
[TBL] [Abstract][Full Text] [Related]
11. Economic burden of adverse events in patients with metastatic renal cell carcinoma.
Hagiwara M; Borker R; Oster G
Clin Ther; 2013 Dec; 35(12):1955-1963.e2. PubMed ID: 24290735
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous complications of molecular targeted therapy used in oncology.
Lupu I; Voiculescu N; Bacalbasa N; Cojocaru I; Vrancian V; Giurcaneanu C
J Med Life; 2016; 9(1):19-25. PubMed ID: 27974909
[TBL] [Abstract][Full Text] [Related]
13. Oral complications of targeted cancer therapies: a narrative literature review.
Watters AL; Epstein JB; Agulnik M
Oral Oncol; 2011 Jun; 47(6):441-8. PubMed ID: 21514211
[TBL] [Abstract][Full Text] [Related]
14. Skin moisturization for xerosis related to targeted anticancer therapies.
Gisondi P; Girolomoni G
J Am Acad Dermatol; 2015 Jul; 73(1):e33. PubMed ID: 26089072
[No Abstract] [Full Text] [Related]
15. Assessment and management of gastrointestinal toxicities and lab abnormalities related to targeted therapy.
Fischer-Cartlidge EA
Semin Oncol Nurs; 2014 Aug; 30(3):183-9. PubMed ID: 25085030
[TBL] [Abstract][Full Text] [Related]
16. Reply to: "Skin moisturization for xerosis related to targeted anticancer therapies".
Valentine J; Belum VR; Duran J; Ciccolini K; Schindler K; Wu S; Lacouture ME
J Am Acad Dermatol; 2015 Jul; 73(1):e35-6. PubMed ID: 26089073
[No Abstract] [Full Text] [Related]
17. Managing Adverse Events With Immune Checkpoint Agents.
Dadu R; Zobniw C; Diab A
Cancer J; 2016; 22(2):121-9. PubMed ID: 27111908
[TBL] [Abstract][Full Text] [Related]
18. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.
Gharwan H; Groninger H
Nat Rev Clin Oncol; 2016 Apr; 13(4):209-27. PubMed ID: 26718105
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy.
Reyes-Habito CM; Roh EK
J Am Acad Dermatol; 2014 Aug; 71(2):217.e1-217.e11; quiz 227-8. PubMed ID: 25037801
[TBL] [Abstract][Full Text] [Related]
20. Anti-vascular endothelial growth factor therapy in the era of personalized medicine.
Féliz LR; Tsimberidou AM
Cancer Chemother Pharmacol; 2013 Jul; 72(1):1-12. PubMed ID: 23463481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
